Filetype
This project aims to develop incretin therapy as a glucose-reducing strategy in type 2 diabetes (T2D). Its particular focus is to understand the mechanisms of incretin therapy and to optimize its clinical positioning. This mission is achieved by an interdisciplinary approach with complementary studies in subjects with T2D, healthy volunteers and experimental animals.
Our research uses advanced technology to generate neurons from novel cell sources with the aim to extensively define the subtype and function of the generated neurons and their potential for therapeutic use in the future. For this we are using reprogramming technology in animal models or human stem cell culture system, together with electrophysiology, RNA sequencing, tracing technologies and cell
Injectable Bioresorbable Organic Bioelectronics Neuropharmacology—our ambition is to supplement classical biochemical signaling with the modulation of bioelectricity using both ionic and electronic processes. We focus on organic electronics that self-assemble directly inside or near the nervous system to form electronic circuits that mimic its structure and organization, enabling seamless integrat
15 april 2026 09:00 | Halvtidskontroll Title: Immunological fitness of lymphocytes in atherosclerosisMain supervisor: Harry BjörkbackaReviewers: Mats Bemark, Annelie Shami, Olof GidlöfAbstractBackgroundAtherosclerosis is a slow, progressive inflammatory disease driven by lipid accumulation and immune cell infiltration over decades. While the involvement of the immune system in plaque development i
https://www.intramed.lu.se/evenemang/samuel-andersson-institutionen-kliniska-vetenskaper-malmo - 2026-05-08
PowerPoint-presentation Header – Optional Introduction – should be maximum three lines. Olo que liciumque porem harum hiliquidis ium quo doloreped qui aperum doluptia perumen ditatestia qui volupta spedipsusam, te plab ipiet voluptusamus alibus ent lit aut qui aut placienem es aliberum sum ea aut harum sit apiciat invenda. Date: 2nd of October 2019 Time: 13.00–15.30 Place: Hörsalen, Pufendorfinsti
https://www.cec.lu.se/sites/cec.lu.se/files/affischmall_a3_cec_2019_eng.pptx - 2026-05-08
OBJECTIVE: To study long-term work disability before and after tumour necrosis factor (TNF)-antagonist therapy in patients with psoriatic arthritis (PsA). METHODS: Using the population-based South Swedish Arthritis Treatment Group Register, we identified 191 patients with PsA (median age 43 years, range 18-58 years, 54% men), who between January 2003 and December 2007 started treatment with adalim
Artificial Intelligence in Cardiothoracic Science was funded 2006. Traditionally, medical decisions are based on the combined strength of clinical facts and the experience of the clinician. A growing understanding of the molecular, genetic and biochemical basis of diseases have greatly increased the degree of complexity in medical decision-making. To identify risk factors in medical registers, a nArtificial Intelligence in Cardiothoracic Science was funded 2006. Traditionally, medical decisions are based on the combined strength of clinical facts and the experience of the clinician. A growing understanding of the molecular, genetic and biochemical basis of diseases have greatly increased the degree of complexity in medical decision-making. To identify risk factors in medical registers, a n
